EU Clinical Trial 2018-004539-54

Capability of Tofacitinib or Etanercept to accelerate clinical relevant tapering of non-steroidal anti-inflammatory drugs and treat-to-target guided de-escalation of corticosteroids in patients with active Rheumatoid Arthrtis and an inadequate response to previous csDMARD therapy  Jun 3, 2019

Main objective of the trial: To demonstrate superiority in the proportion of patients who can discontinue Celecoxib treatment and in whom clinically relevant pain relief is measured, defined as reduction in VAS-pain (0-100 mm) of ≥ 30%, at week 12 compared to baseline in the TOFA group compared to the ETA group

Parties

Sponsors
Countries
BE DE
Keywords
Celebrex Enbrel Rheumatoid arthritis Xeljanz

JSON preview

Similar records

Title

Source:  EMA Last updated:  Jun 5, 2019

From ClinicalTrialsRegister.eu, a database of the European Medicines Agency. This record may not reflect the most current and accurate data available from the EMA.